NCT03954444View on ClinicalTrials.gov

"A Clinical Endpoint Bioequivalence Study of Oxymetazoline Hydrochloride Cream"

PHASE3CompletedINTERVENTIONAL
Enrollment

1,105

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

January 7, 2020

Study Completion Date

February 27, 2020

Conditions
Rosacea
Interventions
DRUG

Oxymetazoline Hydrochloride

Test Comparator

DRUG

Rhofade Cream, 1%

Reference Comparator

DRUG

Placebo

Placebo Comparator

Trial Locations (1)

24501

Site 1, Lynchburg

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Actavis Inc.

INDUSTRY

NCT03954444 - "A Clinical Endpoint Bioequivalence Study of Oxymetazoline Hydrochloride Cream" | Biotech Hunter | Biotech Hunter